Immune to Cancer: The CRI Blog
-
2022 International Cancer Immunotherapy Conference Highlights from Day 4
The final day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) wrapped up an amazing conference… -
2022 International Cancer Immunotherapy Conference Highlights from Day 3
The third day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) focused on two relatively new… -
2022 International Cancer Immunotherapy Conference Highlights from Day 2
The second day of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22) started off by delving deeper… -
2022 International Cancer Immunotherapy Conference Highlights from Day 1
Back for the first time since the COVID-19 pandemic began, the sixth annual CRI-ENCI-AACR International Cancer Immunotherapy… -
From Autoimmunity to Cancer Cures: How Diabetes May Hold the Key to Improving Immunotherapy, with Dr. Andrea Schietinger
Biologically, cancer and autoimmunity don’t seem to have much in common. In fact, they appear to be… -
Immunotherapy for Rare Cancers: New Horizons and New Hope
Rare cancers are more common than many realize. Collectively, they account for nearly one in four cases… -
Understanding and Overcoming Disparities in Cancer Treatment and Care
Cancer not only affects each person differently, but it can also affect different communities overall in different… -
ASCO 2022 Recap: Cancer Immunotherapy Updates
Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought… -
ASCO 2022 Preview: The Latest Insights from the Front Lines of Cancer Immunotherapy
CRI’s PRINCE Trial featured at ASCO22, along with sessions that highlight the latest clinical advances in checkpoint…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.